New fixed dose combination drug for type 2 diabetes

Xigduo (dapagliflozin and metformin hydrochloride in 5mg/850mg and 5mg/1000mg tablets) is now available in the UK for the treatment of appropriate patients with type 2 diabetes. Xigduo is a twice daily tablet that combines dapagliflozin, a selective and reversible inhibitor of SGLT2, with metformin hydrochloride (HCI) and is the first fixed-dose combination of its kind to be available in the UK.Xigduo is now available for use on NHS England and NHS Wales, as NICE and All Wales Medicines Strategy Group (AWMSG) have decided not to appraise it, on the basis that existing guidance for dapagliflozin already covers all patients for